Who Supplies Gliclazide to India from IRELAND

Importing finished pharmaceutical formulations containing Gliclazide into India requires compliance with the Central Drugs Standard Control Organisation (CDSCO) regulations. The importing company must obtain a valid Importer License from the Directorate General of Foreign Trade (DGFT). Each product must be registered with CDSCO, which involves submitting Form 40/41 along with necessary documents such as the Certificate of Pharmaceutical Product (CoPP), Free Sale Certificate, and stability data. The registration process typically takes 6 to 12 months, depending on the completeness of the application and the regulatory workload. For formulations under HS Code 30049099, specific requirements include proof of Good Manufacturing Practice (GMP) compliance and evidence of market authorization in the country of origin. Additionally, a No Objection Certificate (NOC) from the Ministry of Health and Family Welfare may be required for certain products.

Imported Gliclazide formulations must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, adhering to International Council for Harmonisation (ICH) guidelines for Zone IV conditions, must be provided to demonstrate product stability in India's climate. Upon arrival, customs drug inspectors perform port inspections to verify the authenticity and quality of the products. If a batch fails to meet the required standards, it may be rejected, leading to potential delays or destruction of the goods.

Between 2024 and 2026, the CDSCO has implemented several regulatory updates affecting the import of finished pharmaceutical formulations. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially impacting the volume of imports. Bilateral agreements between India and Ireland have facilitated smoother trade relations, including mutual recognition of GMP certifications, which may expedite the import process for Irish suppliers. These developments aim to balance the promotion of domestic industry with the need for high-quality imported pharmaceuticals.

India imports finished Gliclazide formulations to meet the demand for patented and branded products, as well as specific dosage forms not produced domestically. The domestic capacity for manufacturing Gliclazide formulations is limited, leading to a reliance on imports to fulfill market needs. The Indian market for Gliclazide formulations is substantial, with a total export market valued at $300.8 million across 238 exporters to 109 countries. This indicates a significant demand for Gliclazide formulations, both domestically and internationally.

The import duty structure for Gliclazide formulations under HS Code 30049099 includes a Basic Customs Duty (BCD) of 10%. A Social Welfare Surcharge (SWS) of 10% is levied on the BCD, resulting in an effective duty of 11%. The Integrated Goods and Services Tax (IGST) is applicable as per prevailing rates, which are subject to change. There are no specific exemptions or concessional duties for imports from Ireland under the Most Favored Nation (MFN) status. The total landed duty percentage varies based on the IGST rate and any additional cess applicable at the time of import.

India sources Gliclazide formulations from Ireland due to the country's strong pharmaceutical manufacturing capabilities, adherence to international quality standards, and the availability of specialized dosage forms. Irish suppliers, such as Sandoz Canada, offer high-quality products that meet the stringent requirements of the Indian market. While other countries like China, Germany, and the United States also supply Gliclazide formulations, Ireland's competitive advantage lies in its consistent product quality, regulatory compliance, and established trade relations with India. Ireland's share in the Indian Gliclazide import market is growing, reflecting its increasing competitiveness.

India imports Gliclazide formulations from Ireland due to the availability of patented and branded products, as well as specialized dosage forms not produced domestically. Irish manufacturers offer high-quality formulations that meet international standards, ensuring efficacy and safety. The domestic production of Gliclazide formulations is limited, necessitating imports to fulfill market demand. Specific formulations, such as extended-release tablets, are particularly sought after in the Indian market.

When compared to other origins like China, Germany, and the United States, Ireland offers competitive advantages in terms of product quality, regulatory compliance, and reliability. Irish pharmaceutical products are known for their adherence to Good Manufacturing Practice (GMP) standards and consistent quality. While other countries may offer lower prices, Ireland's products provide a balance of quality and cost-effectiveness, making them a preferred choice for Indian importers.

Indian importers face several supply chain risks when sourcing Gliclazide formulations from Ireland, including single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should diversify their supplier base, monitor currency exchange rates, stay updated on regulatory developments, conduct thorough quality checks, and maintain buffer stocks to manage potential shipping delays.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letter of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP) to manage financial risks.
4. 4Minimum Order Quantities (MOQs): Align order quantities with market demand to optimize inventory costs.
5. 5Supplier Qualification: Conduct thorough